Back to Search Start Over

Autobahn Therapeutics Announces FDA Clearance of IND Application for ABX-002 as an Adjunctive Treatment for Bipolar Depression

Source :
Business Wire. October 22, 2024
Publication Year :
2024

Abstract

Company to initiate Phase 2 trial of ABX-002 for bipolar depression by yearend 2024 ABX-002 also being evaluated as an adjunctive treatment for major depressive disorder in the ongoing AMPLIFY [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
Business Wire
Publication Type :
News
Accession number :
edsgcl.813130438